AIM
ZYNE

Acrospire Investment Management’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Acrospire Investment Management’s Portfolio ZYNE Stock Details ZYNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-546
Closed -$11K – 2626
2017
Q1 		$11K Buy
546
+441
+420% +$8.76K 0.01% 1851
2016
Q4 		$2K Buy
+105
New +$1.41K ﹤0.01% 2135

Other funds holding ZYNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
MWNA
Marshall Wace North America New York $23.5B AUM 46.46% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 57.61% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FTIOP
Fiduciary Trust International of Pennsylvania Radnor, Pennsylvania $2.14B AUM 3.72% 1-Year Est. Return

Acrospire Investment Management's ZYNE Position: Q2 2017 in Review

Acrospire Investment Management sold out of Zynerba Pharmaceuticals, Inc (ZYNE) in Q2 2017, closing a stake of 546 shares — an estimated $11K sold.

Acrospire Investment Management first reported a position in ZYNE in Q4 2016 and held it in 2 quarters. The position peaked at $11K in Q1 2017. 66 funds tracked by Wall St. Rank hold ZYNE as of Q2 2017.

  • Acrospire Investment Management reported no remaining Zynerba Pharmaceuticals, Inc position as of Q2 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 546 Zynerba Pharmaceuticals, Inc shares in Q2 2017, an estimated $11K.
  • Acrospire Investment Management first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and held it in 2 quarters.
  • Acrospire Investment Management's Zynerba Pharmaceuticals, Inc position peaked at $11K in Q1 2017.
  • 66 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q2 2017.

Based on Acrospire Investment Management's 13F filing for Q2 2017, filed 11 Aug 2017.